CJC-1295 with DAC: research overview

CJC-1295 with DAC is a long-acting GHRH analog (albumin-bound, plasma half-life 5.8–8.1 days per Teichman 2006). It activates the canonical GHRH receptor — the exact target potentiated by L-arginine in the validated GHRH+arginine diagnostic stimulation test, where arginine roughly doubles peak GH by suppressing hypothalamic somatostatin (Alba-Roth 1988; Ghigo 1990). The Ghigo 2001 review formalizes GHRH plus arginine as a gender- and age-robust probe of somatotroph capacity. This is the strongest mechanistic precedent in the cofactor literature: cofactor and peptide hit the same dual-arm system (arginine releases the somatostatin brake; CJC-1295 DAC presses the GHRH accelerator). No CJC-1295-specific arginine co-administration trial has been published.

Because CJC-1295 with DAC delivers a sustained tonic GHRH signal rather than restoring physiological pulsatility, the endogenous nocturnal GH pulse — which is keyed to slow-wave sleep onset — remains the dominant determinant of total integrated GH exposure in healthy adults. Van Cauter and Plat documented that GHRH is the primary driver of the SWS-coupled pulse and that age-related GH decline tracks SWS loss. Born et al. showed nocturnal GH timing is locked to sleep onset and SWS occurrence. Co-administered behavioral cofactors that preserve SWS architecture (sleep timing, sleep duration) are reported in the broader GH-axis literature as the physiological substrate any exogenous GHRH analog acts on top of.

The dual-input model of GH secretion predicts that combining a GHRH-receptor agonist with a ghrelin-receptor agonist should be synergistic, not additive. Hataya et al. reported in healthy men that low-dose ghrelin co-administered with GHRH drove GH release greater than the sum of individual responses. Cunha and Mayo's transfected-cell work mapped the mechanism: co-activation of GHRH and GHS receptors produces a cAMP signal roughly double GHRH alone, suggesting direct receptor cross-talk. Fintini et al. extended this in GHRH-knockout mice, where a GHRH analog plus the ghrelin-receptor agonist GHRP-2 outperformed monotherapy on growth endpoints. This is the published mechanistic basis for the CJC-1295 DAC + ipamorelin pairing widely discussed in research practice — though no human RCT of that specific pair has been published.

Because CJC-1295 with DAC drives sustained downstream IGF-1 elevation, downstream cofactors of IGF-1 synthesis are mechanistically relevant. Hamza et al. reported that three months of zinc supplementation in pre-pubertal children with biochemical zinc deficiency was followed by significant increases in serum IGF-1 and IGFBP-3 alongside height-SDS gains. Zinc deficiency has been documented as a state in which the GH-to-IGF-1 conversion step is blunted, so deficiency correction would be expected to remove a ceiling on the downstream IGF-1 readout that CJC-1295 DAC is designed to elevate. No CJC-1295 × zinc trial has been published.